Clinical trials Below are current clinical trials.501 studies in Oncology (Medical) (open studies only). Filter this list of studies by location, status and more. A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection Jacksonville, Fla. The purpose of this study is to compare the drug levels of nivolumab administered subcutaneously versus intravenous administration in participants with melanoma following complete resection. A Study To Examine Quality of Life Assessment in Patients Receiving Cryotherapy for Palliation of Dysphagia in Unresectable Esophageal or Gastroesophageal Junctional Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the effect of endoscopic cryoablation for lessening the effects of dysphagia on the quality of life (QOL) of patients with unresectable esophageal or gastroesophageal junctional cancer. 3D Ultrasound Imaging for Breast Cancer Diagnosis Rochester, Minn. The purpose of this study is to evaluate the effectiveess of a new 3D ultrasound imaging technology combining B-mode, microvessel imaging, shear wave elastography, and machine learning for breast lesion diagnosis. A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor Rochester, Minn. This phase III trial compares memantine to usual treatment in treating patients with brain tumors that are newly diagnosed or has come back (recurrent). Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary brain tumor. Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer Rochester, Minn. The purpose of this study is to answer whether plasma circulating tumor DNA (ctDNA) obtained by serial analysis before, during, and following surgery, radiotherapy, chemotherapy, and/or immunotherapy for cervical cancer will allow for risk stratification, individualized treatment decision making, monitoring of treatment response, and early detection of residual or recurrent disease in patients presenting with human papillomavirus (HPV) mediated cervical cancer. A Study to Evaluate Tazemetostat Combined with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma Rochester, Minn., Jacksonville, Fla. The purpose of this study is to evaluate the effectiveness and safety of tazemetostat in combination with R2 in subjects with Relapsed/Refractory Follicular Lymphoma (R/R FL), who have completed at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy. Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study Rochester, Minn. The purpose of this study is to find the maximum tolerated dose of iberdomide for patients newly diagnosed with multiple myeloma, and to determine response rate during induction treatment when combined with daratumumab, bortezomib and dexamethansone. A Study to Evaluate Oncologic Outcomes and Quality of Life in Sinonasal Cancer Patients Rochester, Minn. This is a multi-site study with several other leading centers studying sinonasal cancers. The purpose of this study is to gain a better understanding of the treatment and significant morbidity associated with sinonasal cancer and identify the impact this disease has on quality of life. In addition, several additional endpoints will focus on survival and optimal treatment strategies. Additional components will also included genomic and molecular analysis of tumor tissue as we search for novel targets for therapy. A Study to Evaluate CHIP and Hematological Toxicity After PRRT in Neuroendocrine Tumor Patients Scottsdale/Phoenix, Ariz., Rochester, Minn., Jacksonville, Fla. The purpose of this study is to combine robust clinical data (e.g., prior chemotherapy or radiation exposure, cumulative Peptide Receptor Radionuclide Therapy (PRRT dose)) with genetic and clonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in PRRT-treated neuroendocrine tumor (NET) patients. Patient Adherence and Symptoms During Post-operative Fluid Restriction Protocol After Transsphenoidal Surgery Jacksonville, Fla. The objectives of this study are to survey patients during the post-operative period regarding their experience with fluid restriction including adherence and discomfort, and to document rates of hyponatremia and readmissions in post-operative patients. Advances in endonasal, endoscopic transsphenoidal surgical techniques have decreased complications and length of stay for persons undergoing resection of sellar and suprasellar masses Previous research by investigators now at Mayo (SLS, AQH) has shown that particular interventions including fluid restriction post-operatively decrease patient morbidity (e.g., from hyponatremia) and readmissions while maintaining patient safety. However, the patient perspective on the impact of fluid restriction has not been documented. Pagination Clinical studies PrevPrevious Page Go to page 3030 Go to page 3131 Go to page 3232 Go to page 3333 Go to page 3434 NextNext Page Request an appointment Expertise & rankingsResearch May 09, 2023 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, have been recognized among the top Cancer hospitals in the nation for 2024-2025 by U.S. News & World Report. Learn more about this top honor Oncology (Medical)DepartmenthomeSectionsOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20180179 Medical Departments & Centers Oncology (Medical)